Raquel Abalo

Prof. Dr. Raquel Abalo

Basic Health Sciences, Universidad Rey Juan Carlos, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
KNKulmira Nurgali
Kulmira Nurgali
RJR. Thomas Jagoe
R. Thomas Jagoe
Raquel AbaloRaquel Abalo
Raquel Abalo
Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?

28 March 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
HWHalina Was
Halina Was
ABAgata Borkowska
Agata Borkowska
ABAna Bagues
Ana Bagues
LTLonglong Tu
Longlong Tu
JLJulia Y. H. Liu
Julia Y. H. Liu
Raquel AbaloRaquel Abalo
Raquel Abalo
Since the first clinical trials conducted after World War II, chemotherapeutic drugs have been extensively used in the clinic as the main cancer treatment either alone or as an adjuvant therapy before and after surgery. Although the use of chemotherapeutic drugs improved the survival of cancer patients, these drugs are notorious for causing many severe side effects that significantly reduce the efficacy of anti-cancer treatment and patients’ quality of life. Many widely used chemotherapy drugs including platinum-based agents, taxanes, vinca alkaloids, proteasome inhibitors, and thalidomide analogs may cause direct and indirect neurotoxicity. In this review we discuss the main effects of chemotherapy on the peripheral and central nervous systems, including neuropathic pain, chemobrain, enteric neuropathy, as well as nausea and emesis. Understanding mechanisms involved in chemotherapy-induced neurotoxicity is crucial for the development of drugs that can protect the nervous system, reduce symptoms experienced by millions of patients, and improve the outcome of the treatment and patients’ quality of life.

1 November 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JFJavier Fernández
Javier Fernández
BSBlanca Silván
Blanca Silván
RERodrigo Entrialgo3
Rodrigo Entrialgo3
CVClaudio J. Villar
Claudio J. Villar
Raffaele CapassoRaffaele Capasso
Raffaele Capasso
Raquel AbaloRaquel Abalo
Raquel Abalo
Flavonoids are plant bioactive compounds of great interest in nutrition and pharmacology, due to their remarkable properties as antioxidant, anti-inflammatory, antibacterial, antifungal and antitumor drugs. More than 5000 different flavonoids exist in nature, with a huge structural diversity and a plethora of interesting pharmacological properties. In this work, five flavonoids were tested for their potential use as antitumor drugs against three CRC cell lines (HCT116, HT-29 and T84). These cell lines represent three different stages of this tumor, one of which is metastatic. Xanthohumol showed the best antitumor activity on the three cancer cell lines, even better than that of the clinical drug 5-fluorouracil (5-FU), although no synergistic effect was observed in the combination therapy with this drug. On the other hand, apigenin and luteolin displayed slightly lower antitumor activities on these cancer cell lines but showed a synergistic effect in combination with 5-FU in the case of HTC116, which is of potential clinical interest. Furthermore, a literature review highlighted that these flavonoids show very interesting palliative effects on clinical symptoms such as diarrhea, mucositis, neuropathic pain and others often associated with the chemotherapy treatment of CRC. Flavonoids could provide a double effect for the combination treatment, potentiating the antitumor effect of 5-FU, and simultaneously, preventing important side effects of 5-FU chemotherapy.

3 November 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
RMRachel McQuade
Rachel McQuade
VSVanesa Stojanovska
Vanesa Stojanovska
Raquel AbaloRaquel Abalo
Raquel Abalo
JBJoel Bornstein
Joel Bornstein
KNKulmira Nurgali
Kulmira Nurgali
Gastrointestinal (GI) side-effects of chemotherapy are a debilitating and often overlooked clinical hurdle in cancer management. Chemotherapy-induced constipation (CIC) and diarrhoea (CID) present a constant challenge in the efficient and tolerable treatment of cancer and are amongst the primary contributors to dose reductions, delays and cessation of treatment. Although prevalence of CIC is hard to estimate, it is believed to affect approximately 16% of cancer patients, whilst incidence of CID has been estimated to be as high as 80%. Despite this, the underlying mechanisms of both CID and CIC remain unclear, but are believed to result from a combination of intersecting mechanisms including inflammation, secretory dysfunctions, GI dysmotility and alterations in GI innervation. Current treatments for CIC and CID aim to reduce the severity of symptoms rather than combating the pathophysiological mechanisms of dysfunction, and often result in worsening of already chronic GI symptoms or trigger the onset of a plethora of other side-effects including respiratory depression, uneven heartbeat, seizures and neurotoxicity. Emerging treatments including those targeting the enteric nervous system present promising avenues to alleviate CID and CIC. Identification of potential targets for novel therapies to alleviate chemotherapy-induced toxicity is essential to improve clinical outcomes and quality of life amongst cancer sufferers.

Verified
Journal Article
Open access
PDF file
VMVicente Martinez
Vicente Martinez
Amaia Iriondo-DeHondAmaia Iriondo-DeHond
Amaia Iriondo-DeHond
Francesca BorrelliFrancesca Borrelli
Francesca Borrelli
Raffaele CapassoRaffaele Capasso
Raffaele Capasso
Dolores del CastilloDolores del Castillo
Dolores del Castillo
Raquel AbaloRaquel Abalo
Raquel Abalo
Cannabis sativa is an aromatic annual flowering plant with several botanical varieties, used for different purposes, like the production of fibers, the production of oil from the seeds, and especially for recreational or medical purposes. Phytocannabinoids (terpenophenolic compounds derived from the plant), include the well-known psychoactive cannabinoid Δ9-tetrahydrocannabinol, and many non-psychoactive cannabinoids, like cannabidiol. The endocannabinoid system (ECS) comprises of endocannabinoid ligands, enzymes for synthesis and degradation of such ligands, and receptors. This system is widely distributed in the gastrointestinal tract, where phytocannabinoids exert potent effects, particularly under pathological (i.e., inflammatory) conditions. Herein, we will first look at the hemp plant as a possible source of new functional food ingredients and nutraceuticals that might be eventually useful to treat or even prevent gastrointestinal conditions. Subsequently, we will briefly describe the ECS and the general pharmacology of phytocannabinoids. Finally, we will revise the available data showing that non-psychoactive phytocannabinoids, particularly cannabidiol, may be useful to treat different disorders and diseases of the gastrointestinal tract. With the increasing interest in the development of functional foods for a healthy life, the non-psychoactive phytocannabinoids are hoped to find a place as nutraceuticals and food ingredients also for a healthy gastrointestinal tract function.

1 August 2016 in Pharmacological Reports
Verified
Journal Article
Closed access
Jose UrangaJose Uranga
Jose Uranga
VLVisitación López-Miranda
Visitación López-Miranda
FLFelipe Lombó
Felipe Lombó
Raquel AbaloRaquel Abalo
Raquel Abalo